EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Patient-Derived Organoids in Pancreatic Cancer Pharmacology: From Pharmacotyping Methodology to the AVATAR Phase III Trial and the Pharmacological Frontier

Fahad I Alsaikhan

Drug Design, Development and Therapy · 2026-11 · Volume 20 · 1-14

DOI: 10.2147/dddt.s646519 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2026-11. Verfasst von Fahad I Alsaikhan. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Alsaikhan, F. I. (2026). Patient-Derived Organoids in Pancreatic Cancer Pharmacology: From Pharmacotyping Methodology to the AVATAR Phase III Trial and the Pharmacological Frontier. Drug Design, Development and Therapy, Volume 20, 1-14. https://doi.org/10.2147/dddt.s646519

Vancouver

Alsaikhan FI. Patient-Derived Organoids in Pancreatic Cancer Pharmacology: From Pharmacotyping Methodology to the AVATAR Phase III Trial and the Pharmacological Frontier. Drug Design, Development and Therapy. 2026;Volume 20:1-14. doi:10.2147/dddt.s646519

BibTeX
@article{Alsaikhan2026,
  author = {Alsaikhan, Fahad I},
  title = {Patient-Derived Organoids in Pancreatic Cancer Pharmacology: From Pharmacotyping Methodology to the AVATAR Phase III Trial and the Pharmacological Frontier},
  journal = {Drug Design, Development and Therapy},
  year = {2026},
  volume = {Volume 20},
  pages = {1--14},
  doi = {10.2147/dddt.s646519}
}
Kostenlos starten →